

Freedom of Information Request: 0385 2019/20

It is likely that the Trust does hold all the information you have requested however we are withholding some of this information for the reasons given below.

The Trust does hold this information for Questions 2 – 6 however it is not in a retrievable format. We do not code this information and were we to review individual patient records we would be in breach of the second data protection principle “Personal information must be processed for limited purpose”. We are therefore withholding this information under Section 40 of the Freedom of Information Act.

- 1. Please confirm or deny if University Hospitals Birmingham NHS Foundation Trust holds information on the number of people diagnosed in University Hospitals Birmingham NHS Foundation Trust with early breast cancer in each year from 2013 to 2018.**

If confirm, please release this data.

Queen Elizabeth Hospital Birmingham:

This is reliant on a manual extraction of data by administration teams, therefore the reliability of it is variable. We believe the 2017 figure of 95 is an accurate reflection of the early (TNM stage 1) breast cancer diagnosis.

Public Health England are in receipt of all pathology laboratory results therefore would be able to provide the most accurate count of this marker.

Year	Total Breast Cancer	Early (TNM Stage 1)	Stage 2
2013	470	1	2
2014	396	21	22
2015	382	55	47
2016	385	76	48
2017	331	95	66
2018	380	58	25
2019	448	23	16

Heartlands, Good Hope, and Solihull Hospitals:

This is reliant on a manual extraction of data by administration teams, therefore the reliability of it is variable, we have included the blanks

Year	Total Breast Cancer	Early (Stage 1)	Stage 2	Blank
2013	487	9	4	461
2014	754	70	53	596
2015	787	224	146	337
2016	961	334	195	327
2017	627	151	133	325
2018	812	202	134	401
2019	747	175	120	380

- 2. Please confirm or deny if University Hospitals Birmingham NHS Foundation Trust holds information on the number of people diagnosed in University Hospitals Birmingham NHS Foundation Trust with early breast cancer that were offered tumour profiling tests to guide adjuvant chemotherapy decisions, in each year from 2013 to 2018.**

If confirm, please release this data.

This information is being withheld under Section 40 of the Freedom of Information Act.

- 3. Please confirm or deny if University Hospitals Birmingham NHS Foundation Trust holds information on the number of people diagnosed in University Hospitals Birmingham NHS Foundation Trust with early breast cancer that were tested with tumour profiling tests to guide adjuvant chemotherapy decisions, in each year from 2013 to 2018.**

If confirm, please release this data.

This information is being withheld under Section 40 of the Freedom of Information Act.

- 4. Please confirm or deny if University Hospitals Birmingham NHS Foundation Trust holds information on the number of people diagnosed in University Hospitals Birmingham NHS Foundation Trust with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative and lymph node (LN)-negative (including micrometastatic disease) early breast cancer in each year from 2013 to 2018.**

If confirm, please release this data.

This information is being withheld under Section 40 of the Freedom of Information Act.

- 5. Please confirm or deny if University Hospitals Birmingham NHS Foundation Trust holds information on the numbers of people diagnosed in University Hospitals Birmingham NHS Foundation Trust with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative and lymph node (LN)-negative (including micrometastatic disease) early breast cancer that were offered tumour profiling tests to guide adjuvant chemotherapy decisions in each year from 2013 to 2018.**

If confirm, please release this data.

This information is being withheld under Section 40 of the Freedom of Information Act.

- 6. Please confirm or deny if University Hospitals Birmingham NHS Foundation Trust holds information on the number of people diagnosed University Hospitals Birmingham NHS Foundation Trust with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative and lymph node (LN)-negative (including micrometastatic disease) early breast cancer that were tested with tumour profiling tests to guide adjuvant chemotherapy decisions in each year from 2013 to 2018.**

If confirm, please release this data.

This information is being withheld under Section 40 of the Freedom of Information Act.